Literature DB >> 29464730

Demyelination during anti-tumour necrosis factor therapy for psoriasis.

J M E Boggs1, L Barnes1.   

Abstract

Anti-tumour necrosis factor (anti-TNF) therapies have been associated with neurological complications, including in rare cases demyelinating disease. It is currently unknown whether patients who have received more than one immunosuppressive agent or anti-TNF have a greater risk of demyelination. We report the case of a 37-year-old woman with psoriasis who presented with an acute episode of demyelination while on anti-TNF therapy. This case was complicated by the fact that progressive multifocal leukoencephalopathy was considered the likely diagnosis initially and was only definitively excluded by brain biopsy. This case demonstrates the difficulty establishing the correct diagnosis in patients with atypical presentations on immunomodulating therapies. We present this rare case of demyelination in a patient who received multiple immunosuppressive therapies to highlight this challenging clinical situation and discuss management with a literature review.
© 2018 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29464730     DOI: 10.1111/ced.13412

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  1 in total

1.  The Role of Non-Selective TNF Inhibitors in Demyelinating Events.

Authors:  Line Buch Kristensen; Kate Lykke Lambertsen; Nina Nguyen; Keld-Erik Byg; Helle H Nielsen
Journal:  Brain Sci       Date:  2021-01-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.